Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), sent a letter to President Biden outlining ways the public and private sectors can best work with global partners to ensure that patients around the world get access to COVID vaccines, therapeutics, and diagnostics. The letter, written on behalf of BIO members, highlights the … Continued
The diversity of our adaptive immune system is why people are reacting so differently to the novel coronavirus. No two people present the virus the exact same way to their immune systems. We‘ve evolved in this way as humans to ensure no virus can eradicate our species.
As Congress and the new President lay out their aggressive “100 Day Plans‚” The Biotechnology Innovation Organization (BIO) today released a new blueprint highlighting goals to strengthen America′s innovation ecosystem, end the COVID-19 pandemic, and get more Americans back to work over the first 100 days.
The Biden administration just announced its intent for the United States to join the COVAX vaccine facility, which aims to deliver COVID-19 vaccines to poor and under-developed countries. Dr. Michelle McMurry-Heath, president and CEO of the Biotechnology Innovation Organization (BIO), made the following statement:
Dr. Nancy Messonnier leads the Centers for Disease Control and Prevention’s work to safely vaccinate the country. Whether the question is who to vaccine first, how to restore trust, or how to administer two doses of a vaccine stored at -70 degrees to a nation of 328 million people, she’s got the answers.
COVID threatens those whose immune systems can’t make enough neutralizing antibodies to fight off the viral invaders. But what if scientists could make super-potent antibodies in the lab and infuse them into newly infected patients? That’s exactly what the first FDA-authorized coronavirus antibody treatment has achieved. Its maker, Eli Lilly, has generated clinical evidence that … Continued
Overcrowded hospitals during the pandemic can pose treatment challenges for patients with other serious illnesses. As Kite Pharma CEO Christi Shaw says, “Cancer doesn’t stop in a crisis.” Neither do her company‘s employees, who go to extraordinary lengths to get personalized CAR-T treatments to patients around the world.
As America’s researchers race to develop the scientific solutions needed to eradicate Covid-19, leaders within the Biotechnology Innovation Organization (BIO) released an open letter to their biopharmaceutical colleagues that articulates key principles to ensure the “integrity, transparency, and objective assessment” of Covid-19 clinical data and secure public trust in new medical products developed in response … Continued
BIO’s Industry Analysis Team has reviewed and annotated pipeline data from BioCentury and Biomedtracker to create an interactive view of the Covid-19 pipeline. The team has investigated each drug as to original inventor (company/country), mechanism of action, and strategic approach, as well as de-duplicated programs for the same active ingredient (for example, hydroxychloroquine is counted only … Continued
